A Major Overhaul of Prescription Drug Prices
A negotiation program is projected to save the government tens of billions of dollars in the coming years.
Biden Makes Lower Drug Prices a Centerpiece of His 2024 Campaign
President Biden’s Inflation Reduction Act allows Medicare to negotiate some drug prices, a change that the pharmaceutical industry and Republicans have opposed for decades.
Narcan Available for Over-the-Counter Purchase: What to Know
The overdose-reversal drug should be more widely available, health experts have said. It arrives in many stores next week, no prescription necessary.
Republican Women, Fearing Backlash on Abortion, Pivot to Birth Control
A group of politically vulnerable G.O.P. women has backed legislation that purports to expand birth control access but would have little effect. Critics say the bill is meant to distract from their anti-abortion stances.
Biden Administration Selects Drugs for Medicare Price Negotiations
After his administration announced the first set of medications selected for Medicare price negotiations, President Biden vowed to continue standing up to the pharmaceutical industry over the cost of drugs.
Eliquis and Jardiance Among First Drugs Picked for Medicare Price Negotiations
The price negotiation program, established by Democrats as part of the Inflation Reduction Act, is expected to save the government tens of billions of dollars in the coming years.
Novo Nordisk’s Ozempic and Wegovy Reshape Denmark’s Economy
Novo Nordisk, the Danish company behind two popular obesity medications, is reaping huge profits and is now responsible for most of the country’s economic growth.
The N.Y.C. Neighborhood That’s Getting Even Thinner on Ozempic
Prescriptions for a new class of medications used for diabetes and weight loss are concentrated in the city’s wealthier, whiter and healthier neighborhoods.
New RSV Vaccines Aren’t Covered by Some Health Insurance Plans
The shot is covered by Medicare Part D, but some with private prescription drug coverage are being asked to pay out of pocket.
Mallinckrodt’s Bankruptcy Plan Would Cut Payments to Opioid Victims by $1 Billion
Mallinckrodt Pharmaceuticals had promised $1.7 billion to governments, individuals and others harmed by the opioid crisis.
Call for more information
888-531-0245
info@siii-clinical.com
From research laboratories to clinical settings, SIII integrates the technologies, resources, and expertise our customers need to rise to the next opportunity. SIII is dedicated to exploring and researching the processes and scientific mechanisms underlying the world we live in.